• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Minimal residual disease in multiple myeloma: are we there yet?

作者信息

Devarakonda Srinivas, Jethava Yogesh

机构信息

Division of Hematology, The Ohio State University, Columbus, OH 43210, USA.

Division of Hematology, University of Iowa, Iowa city, IA 52242, USA.

出版信息

Int J Hematol Oncol. 2020 Nov 20;9(4):IJH29. doi: 10.2217/ijh-2020-0018.

DOI:10.2217/ijh-2020-0018
PMID:33294170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7689536/
Abstract
摘要

相似文献

1
Minimal residual disease in multiple myeloma: are we there yet?多发性骨髓瘤中的微小残留病：我们做到了吗？
Int J Hematol Oncol. 2020 Nov 20;9(4):IJH29. doi: 10.2217/ijh-2020-0018.
2
What to do with minimal residual disease testing in myeloma.多发性骨髓瘤微小残留病灶检测的处理方法。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):137-141. doi: 10.1182/hematology.2019000080.
3
Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.多参数流式细胞术评估多发性骨髓瘤微小残留病
Klin Onkol. 2017 Summer;30(Supplementum2):21-28. doi: 10.14735/amko20172S21.
4
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.多发性骨髓瘤微小残留病检测的临床应用及未来方向
Front Oncol. 2020 Jan 31;10:1. doi: 10.3389/fonc.2020.00001. eCollection 2020.
5
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.多发性骨髓瘤的治疗评估和微小残留病灶检测的功能成像。
Int J Mol Sci. 2020 Jul 29;21(15):5406. doi: 10.3390/ijms21155406.
6
Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.多发性骨髓瘤中的微小残留病：对反应评估、预后和肿瘤异质性的影响。
Adv Exp Med Biol. 2018;1100:141-159. doi: 10.1007/978-3-319-97746-1_9.
7
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.微小残留病灶检测在多发性骨髓瘤治疗选择和药物研发中的作用：当前价值与未来应用。
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.
8
Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.全面描绘微小残留病灶中循环和骨髓衍生多发性骨髓瘤细胞的特征。
Semin Hematol. 2018 Jan;55(1):33-37. doi: 10.1053/j.seminhematol.2018.02.010. Epub 2018 Mar 1.
9
Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.在检测多发性骨髓瘤微小残留病方面，经Ficoll分层处理的骨髓优于骨髓血沉棕黄层。
Hematology. 2019 Dec;24(1):533-537. doi: 10.1080/16078454.2019.1637574.
10
Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.通过下一代测序对多发性骨髓瘤进行标准化微小残留病检测
Front Oncol. 2019 Jun 6;9:449. doi: 10.3389/fonc.2019.00449. eCollection 2019.

本文引用的文献

1
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.达雷妥尤单抗、硼替佐米和地塞米松与硼替佐米和地塞米松治疗既往治疗的多发性骨髓瘤患者：CASTOR 的 3 年随访结果。
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518. doi: 10.1016/j.clml.2019.09.623. Epub 2019 Oct 9.
2
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.达雷妥尤单抗联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤：随机、开放标签、3 期 POLLUX 研究的扩展随访。
Leukemia. 2020 Jul;34(7):1875-1884. doi: 10.1038/s41375-020-0711-6. Epub 2020 Jan 30.
3
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.达雷妥尤单抗联合硼替佐米、美法仑和泼尼松治疗新诊断多发性骨髓瘤（ALCYONE）的总生存：一项随机、开放标签、3 期临床试验。
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
4
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
5
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.在靶向治疗药物和免疫治疗时代，使用氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）进行黑色素瘤疗效评估的优势与挑战
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):67-77. doi: 10.1007/s00259-017-3691-7. Epub 2017 Apr 7.
6
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的新一代流式检测技术。
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
7
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
8
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.微小残留病状态在新诊断的多发性骨髓瘤患者临床结局中的作用：一项荟萃分析。
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.
9
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
10
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.流式细胞术检测骨髓瘤微小残留病：每对数级降低对生存获益的独立预测
Blood. 2015 Mar 19;125(12):1932-5. doi: 10.1182/blood-2014-07-590166. Epub 2015 Feb 2.